| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total operating expense | 68,044 | - |
| Other income, net | 1,344 | - |
| Loss on disposal of property and equipment | - | -2 |
| Net loss | -66,700 | -47,964 |
| Depreciation and amortization expense | 766 | 537 |
| Non-cash lease expense | 834 | 508 |
| Stock-based compensation expense | 5,052 | 3,628 |
| Change in fair value of warrant liability | -2,099 | - |
| Offering costs recognized in other expense, net | 2,046 | - |
| Prepaid expenses and other current assets | -509 | -718 |
| Other non-current assets | -670 | -628 |
| Accounts payable | 5,139 | 4,007 |
| Accrued expenses and other current liabilities | -309 | 391 |
| Operating lease liability | -1,202 | -750 |
| Net cash used in operating activities | -55,294 | -38,295 |
| Purchases of property and equipment | 7 | 7 |
| Proceeds from sales of property and equipment | 12 | 12 |
| Proceeds from exercise of common stock options | - | 0 |
| Net cash provided by (used in) investing activities | 5 | 5 |
| Proceeds from issuance of common stock through atm offering, net | 6,454 | 5,940 |
| Proceeds from issuance of common stock and warrants through underwritten offering, net | 27,874 | - |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 223 | 223 |
| Net cash provided by financing activities | 34,551 | 6,163 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -20,738 | -32,127 |
| Cash and cash equivalents at beginning of period | 72,054 | - |
| Cash and cash equivalents at end of period | 51,316 | - |
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR)